The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT

NCT07126782 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

AML (Acute Myelogenous Leukemia)
AML

Interventions

BIOLOGICAL: Ex-vivo expanded allogeneic γδ T cells

Sponsor

Institute of Hematology & Blood Diseases Hospital, China